Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.58 |
| ▸ | PDE2A | O00408 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | MPL | P40238 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30638488 | 1.00 | IDO1 (0.58) | IDO1PDE2ACA1CA2CA9 | |
| SCHEMBL27546311 | 0.84 | IDO1 (0.54) | IDO1PDE2ACA1CA2CA9 | |
| SCHEMBL1117948 | 0.83 | IDO1 (0.58) | IDO1PDE2APTPN1GSK3BMPL | |
| SCHEMBL1018316 | 0.83 | IDO1 (0.43) | IDO1PDE2APTPN1GSK3BTAAR1 | |
| SCHEMBL30149710 | 0.83 | IDO1 (0.43) | IDO1PDE2APTPN1GSK3BTAAR1 | |
| SCHEMBL13208331 | 0.82 | CYP2D6 (0.41) | IDO1 | |
| SCHEMBL18602429 | 0.81 | IDO1 (0.59) | IDO1PDE2ACA1CA2CA9 | |
| SCHEMBL42905 | 0.79 | IDO1 (0.62) | IDO1PDE2ACA1CA2CA9 | |
| SCHEMBL147418 | 0.79 | IDO1 (0.58) | IDO1PDE2ACA1CA2CA9 | |
| SCHEMBL6566 | 0.79 | IDO1 (0.62) | IDO1PDE2ACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326777-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HEPAITECH BEIJING BIOPHARMA TECH CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| WO-2025087761-A1 | PESTICIDALLY ACTIVE CYCLIC AMINE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2025-05-01 | — | — | WO | disclosed |
| US-20250034108-A1 | SODIUM CHANNEL BLOCKERS | NOVARTIS AG (CH) | 2025-01-30 | — | — | US | disclosed |
| US-20240383873-A1 | PESTICIDALLY ACTIVE CYCLIC AMINE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2024-11-21 | — | — | US | disclosed |
| US-20240217950-A1 | PESTICIDALLY ACTIVE CYCLIC AMINE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2024-07-04 | — | — | US | disclosed |
| CN-117642385-A | Pesticidally active cyclic amine compounds | 先正达农作物保护股份公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-4323343-A2 | PYRIDINE DERIVATIVES AND THEIR USE AS PESTICIDE | Syngenta Crop Protection AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| EP-4313966-A1 | PESTICIDALLY ACTIVE CYCLIC AMINE COMPOUNDS | Syngenta Crop Protection AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024026076-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | SEPTERNA, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-117157287-A | Pesticidally active cyclic amine compounds | 先正达农作物保护股份公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-1521757-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| EP-0863875-B1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| CN-1202152-A | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 1998-12-16 | — | — | CN | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217950-A1 | PESTICIDALLY ACTIVE CYCLIC AMINE COMPOUNDS | DDT, ACHE, PNMT | IDO1 84/4885PDE2A 36/4885CA1 1562/4885 |
| US-20250034108-A1 | SODIUM CHANNEL BLOCKERS | SCN5A, SCN2B, SCN1B | IDO1 4789/4885PDE2A 399/4885CA1 1497/4885 |
| US-20240383873-A1 | PESTICIDALLY ACTIVE CYCLIC AMINE COMPOUNDS | DDT, PNMT, ACHE | IDO1 90/4885PDE2A 39/4885CA1 1518/4885 |
| US-20250326777-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | MRGPRX4, MRGPRX1, MRGPRX2 | IDO1 2980/4885PDE2A 196/4885CA1 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.